- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- Fact Check
- Bone Health Fact Check
- Brain Health Fact Check
- Cancer Related Fact Check
- Child Care Fact Check
- Dental and oral health fact check
- Diabetes and metabolic health fact check
- Diet and Nutrition Fact Check
- Eye and ENT Care Fact Check
- Fitness fact check
- Gut health fact check
- Heart health fact check
- Kidney health fact check
- Medical education fact check
- Men's health fact check
- Respiratory fact check
- Skin and hair care fact check
- Vaccine and Immunization fact check
- Women's health fact check
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
GLP-1 receptor agonists and SGLT-2 inhibitors reduce COPD exacerbations among diabetes patients
Canada: A recent study published in the BMJ has highlighted that glucagon-like peptide 1 (GLP-1) receptor agonists, and sodium-glucose co-transporter-2 (SGLT-2) inhibitors are tied to lower risk of Chronic Obstructive Pulmonary Disease (COPD) exacerbation in those patients who have COPD and Type 2 Diabetes. The researchers also added that dipeptidyl peptidase 4 (DPP-4) inhibitors have no clear association in reducing COPD exacerbations.
GLP-1 receptor agonists, DPP-4 inhibitors, and SGLT-2 are commonly used antihyperglycemic. Previous studies have reported their favourable cardiovascular effects. Adding data further, emerging data suggest that these have benefits on lung functions, too, especially among COPD patients.
GLP-1 receptor agonists may improve forced vital capacity in cases of compromised lung function. DPP-4 inhibitors reduce bronchial hyperresponsiveness and increase endogenous GLP-1 concentration. SGLT-2 receptors though not expressed in the lungs but induce glucosuria and reduce pneumonia risk.
The data on the action of antihyperglycaemic on exacerbations in respiratory disease remains limited. The data suggest that DPP-4 inhibitors do not decrease COPD exacerbations, while GLP-1 receptor agonists decrease it by 48% in type 2 diabetes and COPD/asthma. But these studies have not considered other clinically important outcomes.
Against the above background, a study was conducted in the Department of Epidemiology at McGill University, Montreal, QC, Canada, by Richeek Pradhan, a doctoral student. This was a team of researchers, and the co-researcher was Sally Lu.
The key points of the study are:
• The study design was a population-based cohort study.
• Data was from UK national, primary and secondary care datasets.
• The first comparison (first cohort) was between GLP-1 receptor agonists (1252 patients) vs sulfonylureas (14259 patients).
• The second comparison (second cohort) was between DPP-4 inhibitors (8731 patients) vs sulfonylureas (18204 patients).
• The third comparison (third cohort) was between SGLT-2 inhibitors (2956 patients) vs sulfonylureas (10841 patients).
• In the first cohort, patients had a mean age of 66 years with 55 % men and FEV1 ≤ 80% was 61 %.
• In the second cohort, the mean age of patients was 69 years, and 56 % were men. The FEV1 ≤80 % is 61 %.
• In the third cohort, the mean age of patients was 68 years, with 57 % men and FEV1 ≤ 80% was 62%.
• Cox proportional hazards models estimated hazard ratios (HR) and 95% CI of severe exacerbation of COPD separately for the three categories.
• The comparison was made with sulfonylureas.
• GLP-1 receptor agonists decreased 30 % of the risk of COPD severe and moderate exacerbation with HR of 0.70 and 0.63, respectively.
• DPP-4 inhibitors modestly decreased the incidence of exacerbation. The HR for severe and moderate exacerbation was 0.91 and 0.93, respectively. (confidence intervals included the null value).
• SGLT-2 inhibitors were tied to a 38% decreased risk of severe exacerbation with HR 0.62. These were not related to a decrease in moderate exacerbation with HR 1.02
The researchers wrote, "To our knowledge, no real-world study has assessed whether SGLT-2 inhibitors decrease the risk of COPD exacerbations. Since type 2 diabetes patients are at high risk of COPD, we aimed to determine if GLP-1 receptor agonists, DPP-4 inhibitors, and SGLT-2 inhibitors, separately, reduce COPD exacerbation in such cases or not, compared with sulfonylureas."
They said, "We observed a 32% lower incidence of COPD exacerbation during the first year of follow-up (HR 0.68). All three available SGLT-2 inhibitors reduced the risk of severe exacerbations."
While discussing, they mentioned, "Our findings indicate that GLP-1 receptor agonists cause 30% and 37 % lower risk of severe and moderate exacerbation than sulfonylureas. Our study results are in line with recent US IBM MarketScan Commercial Claims Database."
Our study followed patients for up to 14 years, they wrote.
Further reading:
Novel antihyperglycaemic drugs and prevention of chronic obstructive pulmonary disease exacerbations among patients with type 2 diabetes: population based cohort study BMJ 2022; 379.
BDS, MDS in Periodontics and Implantology
Dr. Aditi Yadav is a BDS, MDS in Periodontics and Implantology. She has a clinical experience of 5 years as a laser dental surgeon. She also has a Diploma in clinical research and pharmacovigilance and is a Certified data scientist. She is currently working as a content developer in e-health services. Dr. Yadav has a keen interest in Medical Journalism and is actively involved in Medical Research writing.
Dr Kamal Kant Kohli-MBBS, DTCD- a chest specialist with more than 30 years of practice and a flair for writing clinical articles, Dr Kamal Kant Kohli joined Medical Dialogues as a Chief Editor of Medical News. Besides writing articles, as an editor, he proofreads and verifies all the medical content published on Medical Dialogues including those coming from journals, studies,medical conferences,guidelines etc. Email: drkohli@medicaldialogues.in. Contact no. 011-43720751